Lars Fruergaard Jorgensen has a problem: Too many people want what he’s selling.
Even if the company isn’t quite a household name, the TV jingle for its best-selling drug — “Oh-oh-ohhh, Ozempic!” — might ring in your ears.
Across the United States, Novo Nordisk’s diabetes and weight-loss drugs, Ozempic and Wegovy, have soared to celebrity status and helped make the company Europe’s most valuable public firm.
Last year, when the company was celebrating its centenary, Novo Nordisk’s revenue jumped by a third, to 232 billion Danish kroner, or $33 billion.
“Nobody forecast a 100-year-old company would grow more than 30 percent,” he said, seemingly torn between pride and amazement.
Persons:
Lars Fruergaard Jorgensen, Jorgensen, ” Mr, ”, Wegovy
Organizations:
Novo Nordisk, Novo Nordisk’s, Nordisk
Locations:
Danish, United States, Copenhagen